Genexine succeeds in transferring ‘Interleukin 7’ technology worth of total USD 560 million

Published: 2017-12-27 16:18:09

Updated: 2017-12-27 16:47:46

Genexine succeeded in transferring technology worth of total USD 560 million.

Genexine publicly announced the company signed a technology transfer agreement of ‘Interleukin 7(long-acting IL-7 cytokine designated as GX-17)’ with Chinese I-Mab Biopharma.

The agreement terms and conditions include the exclusive development and sale rights of GX-17, which combined the Genexine’s long-acting tec...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.